Advertisement

Neuroscience and Behavioral Physiology

, Volume 37, Issue 3, pp 203–208 | Cite as

Impairment of memory and attention in the elderly

  • N. N. Yakhno
  • V. V. Zakharov
  • A. B. Lokshina
Article

Keywords

Dementia Cognitive Impairment Mild Cognitive Impairment Memantine Vascular Dementia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    I. V. Damulin, Dyscirculatory Encephalopathy in the Elderly and Aged [in Russian], Author’s abstract of thesis for doctorate in medical sciences, Moscow (1997).Google Scholar
  2. 2.
    I. V. Damulin, Alzheimer’s Disease and Vascular Dementia [in Russian], N. N. Yakhno (ed.), Moscow (2002).Google Scholar
  3. 3.
    I. V. Damulin, V. A. Parfenov, A. A. Skoromets, and N. N. Yakhno, “Circulatory impairments in the brain and spinal cord,” in: Diseases of the Nervous System. Handbook for Doctors [in Russian], N. N. Yakhno and D. R. Shtul’man (eds.), Meditsina, Moscow (2003), Vol. 1, pp. 231–302.Google Scholar
  4. 4.
    V. V. Zakharov, Cognitive Impairments in Parkinson’s Disease and Symptomatic Parkinsonism [in Russian], Author’s abstract of thesis for doctorate in medical sciences, Moscow (2003).Google Scholar
  5. 5.
    V. V. Zakharov and N. N. Yakhno, Memory Impairments [in Russian], GéotarMed, Moscow (2003).Google Scholar
  6. 6.
    V. V. Zakharov, N. V. Yaroslavtseva, and N. N. Yakhno, “Cognitive impairments in Parkinson’s disease,” Nevrol. Zh., 8, No. 2, 11–16, (2003).Google Scholar
  7. 7.
    V. V. Zakharov and A. B. Lokshina, “Use of Pronoran (piribedil) in mild cognitive impairments in elderly patients with dyscirculatory encephalopathy,” Nevrol. Zh., 2, 30–35 (2004).Google Scholar
  8. 8.
    A. B. Lokshina, Mild and Moderate Cognitive Impairments in Dyscirculatory Encephalopathy [in Russian], Author’s abstract of thesis for doctorate in medical sciences, Moscow (2005).Google Scholar
  9. 9.
    N. B. Man’kovskii and A. Ya. Mints, Aging and the Nervous System [in Russian], Kiev (1972).Google Scholar
  10. 10.
    A. V. Obukhova, “Use of the selective D2/D2_receptor agonist Pronoran (piribedil) in the treatment of Parkinson’s disease,” Nevrol. Zh., 3, 38–40 (2002).Google Scholar
  11. 11.
    E. V. Shmidt, “Classification of vascular lesions of the brain and spinal cord,” Zh. Nevropatol. Psikhiat., 85, No. 9, 192–203 (1985).Google Scholar
  12. 12.
    N. N. Yakhno and A. Yu. Lavrov, “Changes in the central nervous system in aging,” in: Neurodegenerative Diseases and Aging (Handbook for Doctors) [in Russian], I. A. Zavalishin, N. N. Yakhno, and S. I. Gavrilova (eds.), Moscow (2001), p. 242–261.Google Scholar
  13. 13.
    N. N. Yakhno, V. V. Zakharov, and A. B. Lokshina, “Moderate cognitive dysfunction syndrome in dyscirculatory encephalopathy,” Zh. Nevrol. Psikhiat., 105, No. 2, 13–17 (2005).Google Scholar
  14. 14.
    N. N. Yakhno, A. B. Lokshina, and V. V. Zakharov, “Mild and moderate cognitive impairments in dyscirculatory encephalopathy,” Klin. Gerontol., 25, No. 11, 38–38 (2005).Google Scholar
  15. 15.
    L. Amaducci and L. Andrea, “The epidemiology of the dementia in Europe,” in: New Concepts in Vascular Dementia, A. Culebras, J. Matias Cuiu, and G. Roman (tds.), Prous Science Publishers, Barcelona (1993), pp. 19–27.Google Scholar
  16. 16.
    L. Bäckman, N. Ginovart, R. Dixon, et al., “Age-related cognitive deficits mediated by changes in the striatal dopamine system,” Amer. J. Psychiat., 157, 635–637 (2000).PubMedCrossRefGoogle Scholar
  17. 17.
    G. Bartoli and E. Wichrowska, “Controlled clinical trial of piribedil in the treatment of cerebrovascular insufficiency,” La. Clin. Ter., 78, No. 2, 141–151 (1976).Google Scholar
  18. 18.
    J. Bille, J. V. Bukiwsky, A. De Ferron, et al., “Decline cerebral et therapeutique: une étude clinique multicentrique de Trivastal 50 retard en Neuro-Geriatrie,” Psych. Med., 18, 609–626 (1986).Google Scholar
  19. 19.
    J. O. Ciocon and J. F. Potter, “Age-related changes in human memory: normal and abnormal,” Norm. Abnorm. Geriat., 43, No. 10, 43–48 (1988).Google Scholar
  20. 20.
    A. DiCarlo, M. Baldereschi, L. Amaducci, et al., “Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging,” J. Amer. Geriat. Soc., 48, 775–782 (2000).Google Scholar
  21. 21.
    M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-Mental State: a practical guide for grading the mental state of patients for the clinician,” J. Psych. Res., 12, 189–198 (1975).CrossRefGoogle Scholar
  22. 22.
    J. Golomb, A. Kluger, P. Garrard, and S. Ferris, Clinician’s Manual on Mild Cognitive Impairment, Science Press, London (2001).Google Scholar
  23. 23.
    J. E. Graham, K. Rockwood, E. L. Beattie, et al., “Prevalence and severity of cognitive impairment with and without dementia in an elderly population,” Lancet, 349, 1793–1796 (1997).PubMedCrossRefGoogle Scholar
  24. 24.
    L. A. Hershey and W. A. Olszewski, “Ischemic vascular dementia,” in: Handbook of Demented Illnesses, J. C. Morris (ed.), Marcel Dekker, New York (1994), pp. 335–351.Google Scholar
  25. 25.
    G. J. Larrabee and T. H. Crook, “Estimated prevalence of age associated memory impairment derived from standardized tests of memory function,” Int. Psychogeriat., 6, No. 1, 95–104 (1994).CrossRefGoogle Scholar
  26. 26.
    R. Levy, “Aging-associated cognitive decline,” Int. Psychogeriat., 6, 63–68 (1994).CrossRefGoogle Scholar
  27. 27.
    S. Lovenstone and S. Gauthier, Management of Dementia, Martin Dunitz, London (2001).Google Scholar
  28. 28.
    D. Nagaraia and S. Jayashree, “Randomised study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment,” Amer. J. Psychiat., 158, No. 9, 1517–1519 (2001).CrossRefGoogle Scholar
  29. 29.
    R. S. Petersen, G. E. Smith, S. C. Waring, et al., “Aging, memory and mild cognitive impairment,” Int. Psychogeriat., 9, 37–43 (1997).CrossRefGoogle Scholar
  30. 30.
    R. S. Petersen, G. E. Smith, S. C. Waring, et al., “Mild cognitive impairment: clinical characterization and outcome,” Arch. Neurol., 56, 303–308 (1999).PubMedCrossRefGoogle Scholar
  31. 31.
    R. S. Petersen, “Current concepts in mild cognitive impairment,” Arch. Neurol., 58, 1985–1992 (2001).PubMedCrossRefGoogle Scholar
  32. 32.
    R. C. Petersen, J. C. Stevens, M. Ganguli, et al., “Practice parameter. Early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, 56, 1133–1142 (2001).PubMedGoogle Scholar
  33. 33.
    K. Ritchie, S. Artero, and J. Touchon, “Classification criteria for mild cognitive impairment: a population-based validation study,” Neurology, 56, 37–42 (2001).PubMedGoogle Scholar
  34. 34.
    W. E. Scholing, “Controlled trial of Trivastal retard 50 and comparison with Trivastal 20 in the treatment of clinical and mental signs of neurovascular disease,” Sci. Med., 4, 4–8 (1977).Google Scholar
  35. 35.
    W. E. Scholing, “A double-blind study using psychometric tests Trivastal versus a reference compound,” Temp. Med., p. 114 (1982).Google Scholar
  36. 36.
    N. Volkow, G. Wang, J. Fowler, et al., “Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging,” Ann. Neurol., 44, No. 1, 143–147 (1998).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • N. N. Yakhno
    • 1
  • V. V. Zakharov
    • 1
  • A. B. Lokshina
    • 1
  1. 1.Department of Nervous DiseasesI. M. Sechenov Moscow Medical AcademyRussia

Personalised recommendations